Related Experiment Video
Updated: Aug 12, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
Published on: February 9, 2011
Serious pediatric infections
1Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston 77030.
Abstract:
Third-generation cephalosporins are important additions to the range of antibiotics available for treating children with serious bacterial infections. They are highly active against the common pathogens, which cause bacterial meningitis in children. Strains of Haemophilus influenzae type b resistant to both ampicillin and chloramphenicol, and Streptococcus pneumoniae relatively resistant to penicillin remain susceptible to cefotaxime and ceftriaxone. Escherichia coli, Klebsiella pneumoniae, Citrobacter diversus, as well as the other more common gram-negative bacilli isolated from neonates and children are susceptible to these agents. However, Listeria monocytogenes is not cephalosporin-sensitive. Ceftazidime is the only third-generation cephalosporin useful for treating serious infections due to Pseudomonas aeruginosa in children. As with other beta-lactam antibiotics, the clearance of cephalosporins is prolonged in neonates, particularly premature babies. Cefotaxime and ceftriaxone are equivalent to ampicillin and chloramphenicol for the treatment of bacterial meningitis in children over two to three months of age with respect to neurologic outcome and safety, despite the in vitro activity of cefotaxime and ceftriaxone being much greater than the standard antibiotics for the meningeal pathogens. Cefotaxime and ceftriaxone are effective in the treatment of serious gram-negative infections in children. In many instances, ceftriaxone can be administered once daily, which allows for more convenient therapy, particularly on an outpatient basis. Although controversial, ceftazidime has been used as single-agent therapy for empiric treatment of neutropenic immunocompromised children with fever.
Insights
Third-generation cephalosporins like cefotaxime and ceftriaxone are effective for serious pediatric bacterial infections, including meningitis. They offer a valuable alternative to older antibiotics, especially against resistant pathogens.
Area of Science:
- Pediatric Infectious Diseases
- Antimicrobial Therapy
- Pharmacology
Background:
- Third-generation cephalosporins represent a significant advancement in treating severe pediatric bacterial infections.
- These antibiotics exhibit high activity against common pathogens responsible for pediatric bacterial meningitis.
- Concerns exist regarding prolonged clearance in neonates, especially premature infants.
Purpose of the Study:
- To evaluate the efficacy and safety of third-generation cephalosporins in treating serious bacterial infections in children.
- To compare third-generation cephalosporins with standard antibiotic treatments for pediatric bacterial meningitis.
- To assess the spectrum of activity against common pediatric pathogens, including resistant strains.
Main Methods:
- Review of in vitro activity against common pediatric pathogens.
- Comparison of cefotaxime and ceftriaxone with ampicillin and chloramphenicol for bacterial meningitis treatment.
- Assessment of safety and neurological outcomes in treated children.
- Evaluation of ceftazidime for Pseudomonas aeruginosa infections and empiric use in neutropenic fever.
Main Results:
- Cefotaxime and ceftriaxone demonstrate high in vitro activity against common meningitis pathogens, including ampicillin/chloramphenicol-resistant Haemophilus influenzae type b and penicillin-resistant Streptococcus pneumoniae.
- These agents are effective against gram-negative bacilli like Escherichia coli and Klebsiella pneumoniae.
- Cefotaxime and ceftriaxone are equivalent to ampicillin and chloramphenicol in neurologic outcome and safety for meningitis in children over 2-3 months.
- Ceftazidime is indicated for Pseudomonas aeruginosa infections; its use in neutropenic fever is noted.
- Listeria monocytogenes is not susceptible to cephalosporins.
Conclusions:
- Third-generation cephalosporins, particularly cefotaxime and ceftriaxone, are effective and safe for treating serious bacterial infections and meningitis in children.
- Ceftriaxone's once-daily dosing offers therapeutic convenience, especially for outpatient treatment.
- Ceftazidime is crucial for Pseudomonas aeruginosa infections, and its empiric use in neutropenic children warrants consideration.
Related Concept Videos
Sexually Transmitted Infections
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Acute Pyelonephritis II: Diagnostic Studies and Management
Viral Meningitis
Bacterial Meningitis I: Introduction
Pneumonia I: Introduction

